Neural correlates of working memory training in HIV patients: study protocol for a randomized controlled trial

L Chang, G C Løhaugen, V Douet, E N Miller, J Skranes, T Ernst, L Chang, G C Løhaugen, V Douet, E N Miller, J Skranes, T Ernst

Abstract

Background: Potent combined antiretroviral therapy decreased the incidence and severity of HIV-associated neurocognitive disorders (HAND); however, no specific effective pharmacotherapy exists for HAND. Patients with HIV commonly have deficits in working memory and attention, which may negatively impact many other cognitive domains, leading to HAND. Since HAND may lead to loss of independence in activities of daily living and negative emotional well-being, and incur a high economic burden, effective treatments for HAND are urgently needed. This study aims to determine whether adaptive working memory training might improve cognitive functions and neural network efficiency and possibly decrease neuroinflammation. This study also aims to assess whether subjects with the LMX1A-rs4657412 TT(AA) genotype show greater training effects from working memory training than TC(AG) or CC(GG)-carriers.

Methods/design: 60 HIV-infected and 60 seronegative control participants will be randomized to a double-blind active-controlled study, using adaptive versus non-adaptive Cogmed Working Memory Training® (CWMT), 20-25 sessions over 5-8 weeks. Each subject will be assessed with near- and far-transfer cognitive tasks, self-reported mood and executive function questionnaires, and blood-oxygenation level-dependent functional MRI during working memory (n-back) and visual attention (ball tracking) tasks, at baseline, 1-month, and 6-months after CWMT. Furthermore, genotyping for LMX1A-rs4657412 will be performed to identify whether subjects with the TT(AA)-genotype show greater gain or neural efficiency after CWMT than those with other genotypes. Lastly, cerebrospinal fluid will be obtained before and after CWMT to explore changes in levels of inflammatory proteins (cytokines and chemokines) and monoamines.

Discussion: Improving working memory in HIV patients, using CWMT, might slow the progression or delay the onset of HAND. Observation of decreased brain activation or normalized neural networks, using fMRI, after CWMT would lead to a better understanding of how neural networks are modulated by CWMT. Moreover, validating the greater training gain in subjects with the LMX1A-TT(AA) genotype could lead to a personalized approach for future working memory training studies. Demonstrating and understanding the neural correlates of the efficacy of CWMT in HIV patients could lead to a safe adjunctive therapy for HAND, and possibly other brain disorders.

Trial registration: ClinicalTrial.gov, NCT02602418.

Figures

Fig. 1
Fig. 1
Study design. We plan to screen ≈ 500 individuals initially by telephone and 200 of these potentially eligible participants in person, to identify ≈ 150 subjects who will fulfill our study criteria, and complete the baseline evaluation. We expect that only ≈ 120 (60 HIV and 60 seronegative) will follow through and be randomized for the training. We also expect that only 85 % (n = 102, 50 HIV, and 52 seronegative) will return for the 1 month follow-up and only 80 % of these (n = 86, 40 HIV, and 42 seronegative) will return to complete the 6-month follow-up evaluations. Furthermore, we expect that ≈ 20 participants who completed the ‘active control’ training will want to continue with the ‘adaptive training’. CSF, cerebrospinal fluid; I/E, inclusion or exclusion; MR, magnetic resonance; SN, seronegative; WM, working memory.

References

    1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16. doi: 10.1007/s13365-010-0006-1.
    1. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67(6):699–714.
    1. Halkitis P, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDS. 2008;22(4):323–35. doi: 10.1089/apc.2007.0122.
    1. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94. doi: 10.1007/s10461-006-9152-0.
    1. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. Aids. 2010;24(9):1243–50.
    1. Chang L, Yakupov R, Nakama H, Stokes B, Ernst T. Antiretroviral treatment is associated with increased attentional load-dependent brain activation in HIV patients. J Neuroimmune Pharmacol. 2008;3(2):95–104. doi: 10.1007/s11481-007-9092-0.
    1. Ernst T, Jiang CS, Nakama H, Buchthal S, Chang L. Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging. 2010;32(5):1045–53. doi: 10.1002/jmri.22366.
    1. Vivithanaporn P, Asahchop EL, Acharjee S, Baker GB, Power C. HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. Aids. 2015
    1. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77(12):1135–42. doi: 10.1212/WNL.0b013e31822f0412.
    1. Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, et al. Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol. 2010;184(2):746–56. doi: 10.4049/jimmunol.0902962.
    1. Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11(1):59–67. doi: 10.1310/hct1101-59.
    1. Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15(2):176–86. doi: 10.1080/13550280902758973.
    1. Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55(1):41–51. doi: 10.1001/archneur.55.1.41.
    1. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology. 2000;54(1):233–5. doi: 10.1212/WNL.54.1.233.
    1. Schifitto G, Yiannoutsos CT, Ernst T, Navia BA, Nath A, Sacktor N, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009;73(23):1975–81. doi: 10.1212/WNL.0b013e3181c51a48.
    1. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69(13):1314–21. doi: 10.1212/01.wnl.0000268487.78753.0f.
    1. Chang L, Jiang C, Cunningham E, Buchthal S, Douet V, Andres M, et al. Effects of APOE epsilon4, age, and HIV on glial metabolites and cognitive deficits. Neurology. 2014;82(24):2213–22. doi: 10.1212/WNL.0000000000000526.
    1. Chang L, Wang GJ, Volkow ND, Ernst T, Telang F, Logan J, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage. 2008;42(2):869–78. doi: 10.1016/j.neuroimage.2008.05.011.
    1. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain. 2004;127(Pt 11):2452–8. doi: 10.1093/brain/awh269.
    1. Yeung H, Krentz HB, Gill MJ, Power C. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. Aids. 2006;20(16):2005–9. doi: 10.1097/01.aids.0000247565.80633.d2.
    1. Cysique LA, Bain MP, Brew BJ, Murray JM. The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future. Sex Health. 2011;8(4):541–50. doi: 10.1071/SH11003.
    1. Wimo A, Winblad B. Pharmacoeconomics of mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:94–9. doi: 10.1034/j.1600-0404.107.s179.13.x.
    1. Bartok JA, Martin EM, Pitrak DL, Novak RM, Pursell KJ, Mullane KM, et al. Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997;3(5):451–6.
    1. Stout JC, Salmon DP, Butters N, Taylor M, Peavy G, Heindel WC, et al. Decline in working memory associated with HIV infection. Psychol Med. 1995;25(6):1221–32. doi: 10.1017/S0033291700033195.
    1. Farinpour R, Martin EM, Seidenberg M, Pitrak DL, Pursell KJ, Mullane KM, et al. Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc. 2000;6(5):548–55. doi: 10.1017/S1355617700655042.
    1. Martin EM, Sullivan TS, Reed RA, Fletcher TA, Pitrak DL, Weddington W, et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7(1):20–6. doi: 10.1017/S1355617701711022.
    1. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Lam MN, Stefaniak M, et al. Verbal and spatial working memory performance among HIV-infected adults. J Int Neuropsychol Soc. 2002;8(4):532–8. doi: 10.1017/S1355617702814278.
    1. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2):152–68. doi: 10.1007/s11065-009-9102-5.
    1. Chang L, Ernst T, Witt M, Ames N, Walot I, Jovicich J, et al. Persistent brain abnormalities in antiretroviral-naïve HIV patients three-months after HAART. Antivir Ther. 2003;8:17–26.
    1. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10(3):317–31. doi: 10.1017/S1355617704102130.
    1. Bassel C, Rourke SB, Halman MH, Smith ML. Working memory performance predicts subjective cognitive complaints in HIV infection. Neuropsychology. 2002;16(3):400–10. doi: 10.1037/0894-4105.16.3.400.
    1. Selnes OA. Neurocognitive aspects of medication adherence in HIV infection. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S132–5. doi: 10.1097/00126334-200212153-00009.
    1. Thames AD, Kim MS, Becker BW, Foley JM, Hines LJ, Singer EJ, et al. Medication and finance management among HIV-infected adults: the impact of age and cognition. J Clin Exp Neuropsychol. 2011;33(2):200–9. doi: 10.1080/13803395.2010.499357.
    1. Klingberg T, Forssberg H, Westerberg H. Training of working memory in children with ADHD. J Clin Exp Neuropsychol. 2002;24(6):781–91. doi: 10.1076/jcen.24.6.781.8395.
    1. Klingberg T, Fernell E, Olesen PJ, Johnson M, Gustafsson P, Dahlstrom K, et al. Computerized training of working memory in children with ADHD – a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2005;44(2):177–86. doi: 10.1097/00004583-200502000-00010.
    1. Johansson B, Tornmalm M. Working memory training for patients with acquired brain injury: effects in daily life. Scand J Occup Ther. 2011;19(2):176–83. doi: 10.3109/11038128.2011.603352.
    1. Westerberg H, Jacobaeus H, Hirvikoski T, Clevberger P, Ostensson ML, Bartfai A, et al. Computerized working memory training after stroke – a pilot study. Brain Inj. 2007;21(1):21–9. doi: 10.1080/02699050601148726.
    1. Lohaugen GC, Antonsen I, Haberg A, Gramstad A, Vik T, Brubakk AM, et al. Computerized working memory training improves function in adolescents born at extremely low birth weight. J Pediatr. 2011;158(4):555–61. doi: 10.1016/j.jpeds.2010.09.060.
    1. Kronenberger WG, Pisoni DB, Henning SC, Colson BG, Hazzard LM. Working memory training for children with cochlear implants: a pilot study. J Speech Lang Hear Res. 2011;54(4):1182–96. doi: 10.1044/1092-4388(2010/10-0119).
    1. Brehmer Y, Westerberg H, Backman L. Working-memory training in younger and older adults: training gains, transfer, and maintenance. Front Hum Neurosci. 2012;6:63. doi: 10.3389/fnhum.2012.00063.
    1. Bell J. The neuropathology of adult HIV infection. Rev Neurol. 1998;154(12):816–29.
    1. Law WA, Martin A, Mapou RL, Roller TL, Salazar AM, Temoshok LR, et al. Working memory in individuals with HIV infection. J Clin Exp Neuropsychol. 1994;16(2):173–82. doi: 10.1080/01688639408402628.
    1. York MK, Franks JJ, Henry RR, Hamilton WJ. Verbal working memory storage and processing deficits in HIV-1 asymptomatic and symptomatic individuals. Psychol Med. 2001;31(7):1279–91. doi: 10.1017/S0033291701004494.
    1. Tomasi D, Ernst T, Caparelli EC, Chang L. Practice-induced changes of brain function during visual attention: a parametric fMRI study at 4 Tesla. NeuroImage. 2004;23(4):1414–21. doi: 10.1016/j.neuroimage.2004.07.065.
    1. van Turennout M, Ellmore T, Martin A. Long-lasting cortical plasticity in the object naming system. Nat Neurosci. 2000;3(12):1329–34. doi: 10.1038/81873.
    1. Grafton ST, Hazeltine E, Ivry R. Functional mapping of sequence learning in normal humans. J Cogn Neurosci. 1995;7:497–510. doi: 10.1162/jocn.1995.7.4.497.
    1. Karni A, Meyer G, Jezzard P, Adams MM, Turner R, Ungerleider LG. Functional MRI evidence for adult motor cortex plasticity during motor skill learning. Nature. 1995;377:155–8. doi: 10.1038/377155a0.
    1. Buchel C, Coull JT, Friston KJ. The predictive value of changes in effective connectivity for human learning. Science. 1999;283(5407):1538–41. doi: 10.1126/science.283.5407.1538.
    1. Garavan H, Kelley D, Rosen A, Rao SM, Stein EA. Practice-related functional activation changes in a working memory task. Microsc Res Tech. 2000;51:54–63. doi: 10.1002/1097-0029(20001001)51:1<54::AID-JEMT6>;2-J.
    1. Jansma JM, Ramsey NF, Slagter HA, Kahn RS. Functional anatomical correlates of controlled and automatic processing. J Cogn Neurosci. 2001;13(6):730–43. doi: 10.1162/08989290152541403.
    1. Olesen PJ, Westerberg H, Klingberg T. Increased prefrontal and parietal activity after training of working memory. Nat Neurosci. 2004;7(1):75–9. doi: 10.1038/nn1165.
    1. Westerberg H, Klingberg T. Changes in cortical activity after training of working memory – a single-subject analysis. Physiol Behav. 2007;92(1–2):186–92. doi: 10.1016/j.physbeh.2007.05.041.
    1. Brehmer Y, Rieckmann A, Bellander M, Westerberg H, Fischer H, Backman L. Neural correlates of training-related working-memory gains in old age. NeuroImage. 2011;58(4):1110–20. doi: 10.1016/j.neuroimage.2011.06.079.
    1. Dahlin E, Neely AS, Larsson A, Backman L, Nyberg L. Transfer of learning after updating training mediated by the striatum. Science. 2008;320(5882):1510–2. doi: 10.1126/science.1155466.
    1. Bellander M, Brehmer Y, Westerberg H, Karlsson S, Furth D, Bergman O, et al. Preliminary evidence that allelic variation in the LMX1A gene influences training-related working memory improvement. Neuropsychologia. 2011;49(7):1938–42. doi: 10.1016/j.neuropsychologia.2011.03.021.
    1. Bellander M, Backman L, Liu T, Schjeide BM, Bertram L, Schmiedek F, et al. Lower baseline performance but greater plasticity of working memory for carriers of the val allele of the COMT Val(1)(5)(8)Met polymorphism. Neuropsychology. 2015;29(2):247–54. doi: 10.1037/neu0000088.
    1. Friling S, Andersson E, Thompson LH, Jonsson ME, Hebsgaard JB, Nanou E, et al. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci USA. 2009;106(18):7613–8. doi: 10.1073/pnas.0902396106.
    1. Nakatani T, Kumai M, Mizuhara E, Minaki Y, Ono Y. Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon. Dev Biol. 2010;339(1):101–13. doi: 10.1016/j.ydbio.2009.12.017.
    1. Smidt MP, Burbach JP. How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci. 2007;8(1):21–32. doi: 10.1038/nrn2039.
    1. Bergman O, Hakansson A, Westberg L, Belin AC, Sydow O, Olson L, et al. Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson’s disease? J Neural Transm. 2009;116(3):333–8. doi: 10.1007/s00702-009-0187-z.
    1. Bergman O, Westberg L, Nilsson LG, Adolfsson R, Eriksson E. Preliminary evidence that polymorphisms in dopamine-related transcription factors LMX1A, LMX1B and PITX3 are associated with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1094–7. doi: 10.1016/j.pnpbp.2010.05.032.
    1. Berger JR, Kumar M, Kumar A, Fernandez J, Levin B. Cerebrospinal fluid dopamine in HIV-1 infection. Acquir Immunodef Syndr. 1994;8(1):67–71.
    1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99. doi: 10.1212/01.WNL.0000287431.88658.8b.
    1. Lohaugen GC, Antonsen I, Haberg A, Gramstad A, Vik T, Brubakk AM, et al. Computerized working memory training improves function in adolescents born at extremely low birth weight. J Pediatr. 2010;158(4):555–61. doi: 10.1016/j.jpeds.2010.09.060.
    1. Spreen O, Strauss E. A compendium of neuropsychological tests: administration, norms and commentary. New York: Oxford University Press; 1998.
    1. Pylyshyn ZW, Storm RW. Tracking multiple independent targets: evidence for a parallel tracking mechanism. Spat Vis. 1988;3(3):179–97. doi: 10.1163/156856888X00122.
    1. Jovicich J, Peters RJ, Koch C, Braun J, Chang L, Ernst T. Brain areas specific for attentional load in a motion tracking task. J Cogn Neurosci. 2001;13:1048–58. doi: 10.1162/089892901753294347.
    1. Flak MM, Hernes SS, Skranes J, Lohaugen GC. The Memory Aid study: protocol for a randomized controlled clinical trial evaluating the effect of computer-based working memory training in elderly patients with mild cognitive impairment (MCI) Trials. 2014;15:156. doi: 10.1186/1745-6215-15-156.
    1. Clark AK, Staniland AA, Malcangio M. Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol. 2011;12(10):1707–14. doi: 10.2174/138920111798357465.
    1. Yang L, Beal MF. Determination of neurotransmitter levels in models of Parkinson’s disease by HPLC-ECD. Methods Mol Biol. 2011;793:401–15. doi: 10.1007/978-1-61779-328-8_27.
    1. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73(3):751–4. doi: 10.1093/biomet/73.3.751.
    1. Becker JT, Dew MA, Aizenstein HJ, Lopez OL, Morrow L, Saxton J, et al. A pilot study of the effects of internet-based cognitive stimulation on neuropsychological function in HIV disease. Disabil Rehabil. 2012;34(21):1848–52. doi: 10.3109/09638288.2012.667188.
    1. Diamond A, Lee K. Interventions shown to aid executive function development in children 4 to 12 years old. Science. 2011;333(6045):959–64. doi: 10.1126/science.1204529.
    1. Chang L, Speck O, Miller E, Braun A, Jovicich J, Koch C, et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology. 2001;57:1001–7. doi: 10.1212/WNL.57.6.1001.
    1. Tomasi D, Chang L, de Castro CE, Telang F, Ernst T. The human immunodeficiency virus reduces network capacity: acoustic noise effect. Ann Neurol. 2006;59(2):419–23. doi: 10.1002/ana.20766.
    1. Chang L, Tomasi D, Yakupov R, Lozar C, Arnold S, Caparelli E, et al. Adaptation of the attention network in human immunodeficiency virus brain injury. Ann Neurol. 2004;56(2):259–72. doi: 10.1002/ana.20190.
    1. Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology. 2002;59(9):1343–9. doi: 10.1212/01.WNL.0000031811.45569.B0.
    1. Ernst T, Chang L, Arnold S. increased glial markers predict increased working memory network activation in HIV patients. NeuroImage. 2003;19(4):1686–93. doi: 10.1016/S1053-8119(03)00232-5.
    1. Ernst T, Yakupov R, Nakama H, Crocket G, Cole M, Watters M, et al. Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol. 2009;65(3):316–25. doi: 10.1002/ana.21594.
    1. Bousman CA, Cherner M, Atkinson JH, Heaton RK, Grant I, Everall IP, et al. COMT Val158Met polymorphism, executive dysfunction, and sexual risk behavior in the context of HIV infection and methamphetamine dependence. Interdiscip Perspect Infect Dis. 2010;2010:678648.
    1. Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol. 2010;5(3):294–309. doi: 10.1007/s11481-010-9205-z.
    1. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17(1):63–9. doi: 10.1007/s13365-010-0013-2.
    1. Chang L, Ernst T, Witt M, Ames N, Jocivich J, Speck O, et al. Relationships among cerebral metabolites, cognitive function and viral loads in antiretroviral-naïve HIV patients. NeuroImage. 2002;17(3):1638–48. doi: 10.1006/nimg.2002.1254.
    1. Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther. 2004;9(3):431–40.
    1. Tomasi D, Volkow ND, Wang R, Telang F, Wang GJ, Chang L, et al. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. PLoS One. 2009;4(6):e6102. doi: 10.1371/journal.pone.0006102.
    1. McNab F, Varrone A, Farde L, Jucaite A, Bystritsky P, Forssberg H, et al. Changes in cortical dopamine D1 receptor binding associated with cognitive training. Science. 2009;323(5915):800–2. doi: 10.1126/science.1166102.
    1. Denkinger MD, Nikolaus T, Denkinger C, Lukas A. Physical activity for the prevention of cognitive decline: current evidence from observational and controlled studies. Z Gerontol Geriatr. 2012;45(1):11–6. doi: 10.1007/s00391-011-0262-6.
    1. Hindin SB, Zelinski EM. Extended practice and aerobic exercise interventions benefit untrained cognitive outcomes in older adults: a meta-analysis. J Am Geriatr Soc. 2012;60(1):136–41. doi: 10.1111/j.1532-5415.2011.03761.x.
    1. Drummond SP, Anderson DE, Straus LD, Vogel EK, Perez VB. The effects of two types of sleep deprivation on visual working memory capacity and filtering efficiency. PLoS One. 2012;7(4):e35653. doi: 10.1371/journal.pone.0035653.
    1. Hollingshead A. Four Factor Index of Social Status. New Haven, CT: Yale University; 1975.
    1. Eaton WW, Smith C, Ybarra M, Muntaner C, Tien A. Center for Epidemiologic Studies Depression Scale: Review and Revision (CESD and CESD-R) In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment. Mahwah, NJ: Lawrence Erlbaum; 2004. pp. 363–77.
    1. Lazowski L, Miller F, Boye M, Miller G. Efficacy of the Substance Abuse Subtle Screening Inventory-3 (SASSI-3) in identifying substance dependence disorders in clinical settings. J Pers Assess. 1998;71(1):114–28. doi: 10.1207/s15327752jpa7101_8.
    1. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86. doi: 10.1093/geront/9.3_Part_1.179.
    1. Buysse DJ. Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.
    1. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV) Qual Life Res. 1997;6(6):481–93. doi: 10.1023/A:1018451930750.
    1. Group WHOsQoL . Development of the World Health Organization Quality of Life Instrument (WHOQOL). Measuring quality of life. Geneva: World Health Organization; 1992.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa